Financials in USD. Standardized financial statements.
A compact view of how Comera Life Sciences Holdings, Inc. turns revenue into operating income and net income.
| Metric | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|
| Revenue? | $633,102 | $319,832 | $442,919 |
| Revenue Growth? | +97.9% | -27.8% | 0.0% |
| Cost of Revenue? | $210,390 | $161,008 | $104,407 |
| Gross Profit? | $422,712 | $158,824 | $338,512 |
| Gross Margin? | +66.8% | +49.7% | +76.4% |
| Operating Expenses? | $12.39M | $5.69M | $2.47M |
| Operating Income? | -$11.97M | -$5.54M | -$2.13M |
| EBITDA? | -$17.89M | -$5.37M | -$2.04M |
| Income Before Tax | -$18.00M | -$5.45M | -$2.13M |
| Income Tax Expense | $0 | $0 | $0 |
| Net Income? | -$18.00M | -$5.45M | -$2.13M |
| EPS? | $-1.76 | $-0.29 | $-0.11 |
| Diluted EPS? | $-1.76 | $-0.29 | $-0.11 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality